Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 November 2015Next earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:12:48 GMTDividend
Analysts recommendations
Institutional Ownership
VYGR Latest News
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotech company focused on advancing neurogenetic medicines, announced today that the initial participants have received doses in a Phase 1a trial of VY-TAU01, an experimental anti-tau antibody designed to block the spread of pathological tau in Alzheimer's disease.
Voyager Therapeutics (VYGR) reported a quarterly loss of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.44. This is a decrease from earnings of $2.94 per share in the same quarter last year.
The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation. Voyager's investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Voyager Therapeutics (NASDAQ: VYGR ) stock is up by more than 25% today after the company agreed to a licensing deal with Novartis (NYSE: NVS ). Novartis will pay $100 million upfront in a “target-exclusive license” for Voyager's RNA-based screening platform and access to a Huntington's Disease treatment that is in pre-clinical trials.
Voyager Therapeutics is a biotech firm focused on gene therapy treatments for CNS diseases, with preclinical trials for Parkinson's, ALS, and Alzheimer's. The company's TRACER platform allows for the delivery of therapeutic genes to previously inaccessible brain regions, unlocking potential drug delivery mechanisms. Voyager has secured partnerships and licensing agreements with major pharmaceutical companies, including Novartis, Pfizer, and Neurocrine, showcasing the value of its IP.
What type of business is Voyager Therapeutics?
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
What sector is Voyager Therapeutics in?
Voyager Therapeutics is in the Healthcare sector
What industry is Voyager Therapeutics in?
Voyager Therapeutics is in the Biotechnology industry
What country is Voyager Therapeutics from?
Voyager Therapeutics is headquartered in United States
When did Voyager Therapeutics go public?
Voyager Therapeutics initial public offering (IPO) was on 11 November 2015
What is Voyager Therapeutics website?
https://www.voyagertherapeutics.com
Is Voyager Therapeutics in the S&P 500?
No, Voyager Therapeutics is not included in the S&P 500 index
Is Voyager Therapeutics in the NASDAQ 100?
No, Voyager Therapeutics is not included in the NASDAQ 100 index
Is Voyager Therapeutics in the Dow Jones?
No, Voyager Therapeutics is not included in the Dow Jones index
When does Voyager Therapeutics report earnings?
The next expected earnings date for Voyager Therapeutics is 02 August 2024